3 Major Reasons for Investors to Buy AbbVie Stock Before July 31st

AbbVie (ABBV) is a strong buy for investors due to its impressive growth at a reasonable valuation, a substantial 5.5% dividend increase, and the successful navigation of the patent cliff that now faces competitors like Merck. The company's key drugs, Skyrizi and Rinvoq, have become major growth drivers, generating significant revenue that has replaced Humira's declining sales. Investors should consider these factors before the Q2 earnings report on July 31st.